常规治疗与胸腺肽-α1治疗慢性阻塞性肺疾病急性加重期合并肺结核患者的应用效果及对其免疫功能的影响  

The application effect of conventional treatment and thymosin-α1 in the treatment of patients with chronic obstructive pulmonary disease in acute exacerbation of pulmonary tuberculosis and its influence on immune function

作　　者：高蕊 GAO Rui(Department of Emergency,Shenyang Fourth People's Hospital,Shenyang,Liaoning,110031,China)

机构地区：[1]沈阳市第四人民医院急诊科,辽宁沈阳110031

出　　处：《当代医学》2022年第1期78-81,共4页Contemporary Medicine

摘　　要：目的分析常规治疗与胸腺肽-α1治疗慢性阻塞性肺疾病(COPD)急性加重期合并肺结核患者的应用效果及对其免疫功能的影响。方法选取2016年12月至2018年12月本院收治的122例COPD急性加重期合并肺结核患者作为研究对象,将2016年12月至2017年11月收治的61例患者作为参照组,并给予抗生素、解痉、平喘等常规治疗;将2017年12月至2018年12月收治的61例患者作为研究组,在参照组治疗的基础上联合胸腺肽-α1治疗,比较两组临床疗效、炎症因子、免疫功能。结果治疗后,研究组治疗总有效率为93.72%,显著高于参照组的86.89%(P<0.05);治疗6周后,两组IL-6、TNF-α水平均低于治疗前,且研究组低于参照组(P<0.05);治疗后,研究组CD3^(+)、CD4^(+)、CD8^(+)水平均高于参照组,CD4^(+)/CD8^(+)水平低于参照组(P<0.05)。结论常规治疗联合胸腺肽-α1治疗COPD急性加重期合并肺结核患者疗效显著,且可减轻机体炎症反应,提高免疫功能。Objective To analyze the effect of conventional treatment and thymosin-α1 in the treatment of patients with chronic obstructive pulmonary disease(COPD) in acute exacerbation of pulmonary tuberculosis and the influence on its immune function. Methods 122 patients with acute exacerbation of COPD and pulmonary tuberculosis admitted to our hospital from December 2016 to December 2018 were selected as the research subjects, and 61 patients admitted from December 2016 to November 2017 were selected as the reference group and given antibiotics, antispasmodic, anti-asthmatic and other conventional treatments;61 patients admitted from December 2017 to December 2018 were selected as the study group, and thymosin-α1 treatment was combined on the basis of the reference group. The clinical efficacy, inflammatory factors, and immune function were compared between the two group. Results After treatment, the treatment effect of the study group was 93.72%, which was significantly higher than 86.89% of the reference group(P<0.05);after 6 weeks of treatment, the levels of IL-6 and TNF-α in the two groups were significantly reduced, and the study group was lower than the reference group(P<0.05);the levels of CD3^(+), CD4^(+), and CD8^(+) in the study groups were higher than the reference group, and the CD4^(+)/CD8^(+) was lower than the reference group(P<0.05). Conclusion Conventional treatment combined with thymosin-α1 is effective in treating patients with COPD in acute exacerbation of pulmonary tuberculosis, and can reduce the body’ s inflammatory response and improve immune function.

关 键 词：常规治疗 胸腺肽-Α1 COPD 急性加重期 肺结核 免疫功能 

分 类 号：R563.9[医药卫生—呼吸系统]